A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non–small cell lung cancer: Hoosier Cancer Research Network LUN 14‐179-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non–small cell lung cancer: Hoosier Cancer Research Network LUN 14‐179

Published:2020-07-22 Issue:19 Volume:126 Page:4353-4361
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Durm Greg A.¹^ORCID,Jabbour Salma K.²,Althouse Sandra K.³,Liu Ziyue³,Sadiq Ahad A.⁴,Zon Robin T.⁵,Jalal Shadia I.¹⁶,Kloecker Goetz H.⁷,Williamson Michael J.⁸,Reckamp Karen L.⁹,Langdon Robert M.¹⁰,Kio Ebenezer A.¹¹,Gentzler Ryan D.¹²,Adesunloye Bamidele A.¹³,Harb Wael A.¹⁴,Walling Radhika V.¹⁵,Titzer Michael L.¹⁶,Hanna Nasser H.¹

Affiliation:

1. Indiana University Melvin and Bren Simon Cancer Center Indianapolis Indiana

2. Rutgers Cancer Institute of New Jersey New Brunswick New Jersey

3. Department of Biostatistics Indiana University Indianapolis Indiana

4. Fort Wayne Medical Oncology and Hematology Fort Wayne Indiana

5. Michiana Hematology Oncology South Bend Indiana

6. Richard L. Roudebush VA Medical Center Indianapolis Indiana

7. James Graham Brown Cancer Center University of Louisville Louisville Kentucky

8. Indiana University Health Ball Memorial Cancer Center Muncie Indiana

9. City of Hope Comprehensive Cancer Center Duarte California

10. Nebraska Methodist Hospital Omaha Nebraska

11. Goshen Center for Cancer Care Goshen Indiana

12. University of Virginia Charlottesville Virginia

13. Indiana University Health Arnett Cancer Center Lafayette Indiana

14. Horizon Oncology Center Lafayette Indiana

15. Community Regional Cancer Center Indianapolis Indiana

16. Oncology Hematology Associates of Southwest Indiana Newburgh Indiana

Funder

Merck

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.33083

Reference23 articles.

1. Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung Cancer

2. Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non–Small-Cell Lung Cancer: KCSG-LU05-04

3. Induction Chemotherapy Followed by Chemoradiotherapy Compared With Chemoradiotherapy Alone for Regionally Advanced Unresectable Stage III Non–Small-Cell Lung Cancer: Cancer and Leukemia Group B

4. Phase III Study of Cisplatin, Etoposide, and Concurrent Chest Radiation With or Without Consolidation Docetaxel in Patients With Inoperable Stage III Non–Small-Cell Lung Cancer: The Hoosier Oncology Group and U.S. Oncology

5. Is Consolidation Chemotherapy after Concurrent Chemo-Radiotherapy Beneficial for Patients with Locally Advanced Non–Small-Cell Lung Cancer?: A Pooled Analysis of the Literature

Cited by 105 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ImmunoChemoradiation for Non-Small Cell Lung Cancer: A Meta-Analysis of Factors Influencing Survival Benefit in Combination Trials;International Journal of Radiation Oncology*Biology*Physics;2024-10

2. Abscopal effect: from a rare phenomenon to a new frontier in cancer therapy;Biomarker Research;2024-09-04

3. Treatment of unresectable stage III non-small cell lung cancer for patients who are under-represented in clinical trials;Cancer Treatment Reviews;2024-09

4. Predictive value of primary tumor volume change during concurrent chemoradiotherapy in patients with unresectable stage III non-small cell lung cancer;Radiotherapy and Oncology;2024-09

5. Comparison of radiotherapy versus surgical resection following neoadjuvant chemoimmunotherapy in potentially resectable stage III non-small-cell lung cancer: A propensity score matching analysis;Lung Cancer;2024-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3